Trial Profile
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Dec 2015
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 04 Dec 2015 New trial record